Figure 5
Comparison of direct oncolytic Ads dose versus oAd-MSC dose. Comparison of direct oncolytic Ads dose with the dose of oAd-MSCs that promote tumor growth ((A) by 10%(δp/s = 0.1), (B) by 50%(δp/s = 0.5), and (C) by 90%(δp/s = 0.9)), and with oAd-MSCs that suppress tumor growth ((D) by 10%(δp/s = 0.1), (E) by 50%(δp/s = 0.5), and (F) by 90%(δp/s = 0.9)). Note the following notation for treatment scenarios: No therapy (00), direct injection of naked oncolytic Ads only (01), injection of oAd-MSCs only (10). The low promotive/suppressive probability (δp/s = 0.1) in (A,D) indicates negligible advantage of oAd-MSC therapy over the therapy naked oncolytic Ads. Also note that at higher probability (δp/s = 0.9), in (C,F), the oAd-MSC therapy reduces tumor burden faster than the naked oncolytic Ads. This indicates that if the oAd-MSCs have a high chance of promoting/suppressing tumor cell proliferation, then the oAd-MSC therapy provides better therapeutic outcomes, as compared with direct intravenous dose of naked oncolytic Ads.
